Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Prior treatment

• A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
• There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)

Other illness

• A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
• A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)

Lab values

• LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available

Other

• Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
• Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
• There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)

• 18 years or older at the time of consent
• A known diagnosis of interstitial lung disease
• Diffusing capacity for carbon monoxide (DLCO) \<30% predicted, collected within 6 months prior to consent
• Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required